Cybin CEO Doug Drysdale talks to Jason Najum about treating mental health disorders with psychedelics and attracting new buyers with its stock price.

Psychoactive chemicals 5-methoxy-dimethyltryptamine and bufotenin are released by toads. A single treatment produced ...

Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry ...

Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, ...